Abstract
A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.
Keywords: Drug induced hepatic failure, AIDS combination therapy, antiretroviral, NNRTI, Emtricitabine, hepatic failure, hepatotoxicity, gonococcal, syphilis, genital herpes
Current Drug Safety
Title:Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure
Volume: 7 Issue: 5
Author(s): Sohail Qayyum, Huijun Dong, Dianne Kovacic, Sidra Sohail, Bradford Waters, Camille Thornton and Cathy E. Corbett
Affiliation:
Keywords: Drug induced hepatic failure, AIDS combination therapy, antiretroviral, NNRTI, Emtricitabine, hepatic failure, hepatotoxicity, gonococcal, syphilis, genital herpes
Abstract: A single pill daily fixed dose combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) provides a potent and convenient treatment option for HIV/AIDS. The components have been shown to be well tolerated and are effective in randomized controlled trials. A literature search revealed no case of hepatic failure reported with this drug combination. We here in describe the 1st case of acute hepatic failure developing after 3 months of treatment with EFV/FTC/TDF in a 41 year old African American male without pre-existing liver disease or risk factors.
Export Options
About this article
Cite this article as:
Qayyum Sohail, Dong Huijun, Kovacic Dianne, Sohail Sidra, Waters Bradford, Thornton Camille and E. Corbett Cathy, Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure, Current Drug Safety 2012; 7 (5) . https://dx.doi.org/10.2174/1574886311207050013
DOI https://dx.doi.org/10.2174/1574886311207050013 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Virulence Determinants of Equine Infectious Anemia Virus
Current HIV Research Bridging Intravenous Thrombolysis Before Mechanical Thrombectomy for Large Artery Occlusion May be Detrimental with Thrombus Fragmentation
Current Neurovascular Research A Pathological Brain Detection System based on Extreme Learning Machine Optimized by Bat Algorithm
CNS & Neurological Disorders - Drug Targets Sirtuins and Resveratrol-Derived Compounds: A Model for Understanding the Beneficial Effects of the Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D’s Molecular Action Mechanism in Attention-Deficit/ Hyperactivity Disorder: A Review of Evidence
CNS & Neurological Disorders - Drug Targets Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Current Cardiology Reviews Concentration and Fractionation of Polyphenols by Membrane Operations
Current Pharmaceutical Design Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Hyperhomocysteinemia, Pteridines and Oxidative Stress
Current Drug Metabolism Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Specific Nutritional Supplement (Supportan<sup>®</sup>) in the Supportive Care of the Radio-Chemotherapy Treatment of Head and Neck Cancers: Biochemical Parameters. Preliminary Study
Endocrine, Metabolic & Immune Disorders - Drug Targets The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Getting an Insight into the Complexity of Major Chronic Inflammatory and Degenerative Diseases: A Potential New Systemic Approach to Their Treatment
Current Pharmaceutical Biotechnology Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents
Current Medicinal Chemistry From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders
Current Molecular Medicine Triamcinolone Acetonide Suppresses Inflammation and Facilitates Vascular Barrier Function in Human Retinal Microvascular Endothelial Cells
Current Neurovascular Research Gene Therapy-Mediated Modulation of Immune Processes in the Central Nervous System
Current Pharmaceutical Design Current Acetylcholinesterase-Inhibitors: A Neuroinformatics Perspective
CNS & Neurological Disorders - Drug Targets Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry